1. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P et al: Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009, 10(11):1111-1118.
2. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. 2019, 144(8):1941-1953.
3. Dhanasekaran R, Nault JC, Roberts LR, Zucman-Rossi J: Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology 2019, 156(2):492-509.
4. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018, 69(1):182-236.
5. Smallwood A, Hon GC, Jin F, Henry RE, Espinosa JM, Ren B: CBX3 regulates efficient RNA processing genome-wide. Genome Res 2012, 22(8):1426-1436.
6. Akaike Y, Kuwano Y, Nishida K, Kurokawa K, Kajita K, Kano S, Masuda K, Rokutan K: Homeodomain-interacting protein kinase 2 regulates DNA damage response through interacting with heterochromatin protein 1γ. Oncogene 2014, 34(26):3463-3473.
7. Rupaimoole R, Slack FJ: MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 2017, 16(3):203-222.
8. Hayes J, Peruzzi PP, Lawler S: MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 2014, 20(8):460-469.
9. Zhu W, Li H, Yu Y, Chen J, Chen X, Ren F, Ren Z, Cui G: Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients. Cancer Manag Res 2018, 10:5735-5745.
10. Bao J, Yu Y, Chen J, He Y, Chen X, Ren Z, Xue C, Liu L, Hu Q, Li J et al: MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. Cell Death Dis 2018, 9(10):1045.
11. Yang L, Yin D, Wang Y, Cao L: Inhibition of the growth of hepatocellular carcinoma cells through fibroblast growth factor 18 suppressed by miR-139. Oncol Rep 2017, 38(4):2565-2571.
12. Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, Man K, Ng IO: The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology 2011, 140(1):322-331.
13. Gu W, Li X, Wang J: miR-139 regulates the proliferation and invasion of hepatocellular carcinoma through the WNT/TCF-4 pathway. Oncol Rep 2014, 31(1):397-404.
14. Sridharan R, Gonzales-Cope M, Chronis C, Bonora G, McKee R, Huang C, Patel S, Lopez D, Mishra N, Pellegrini M et al: Proteomic and genomic approaches reveal critical functions of H3K9 methylation and heterochromatin protein-1gamma in reprogramming to pluripotency. Nat Cell Biol 2013, 15(7):872-882.
15. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
16. Dialynas GK, Vitalini MW, Wallrath LL: Linking Heterochromatin Protein 1 (HP1) to cancer progression. Mutat Res 2008, 647(1-2):13-20.
17. Chang C, Liu J, He W, Qu M, Huang X, Deng Y, Shen L, Zhao X, Guo H, Jiang J et al: A regulatory circuit HP1gamma/miR-451a/c-Myc promotes prostate cancer progression. Oncogene 2018, 37(4):415-426.
18. Chang SC, Lai YC, Chen YC, Wang NK, Wang WS, Lai JI: CBX3/heterochromatin protein 1 gamma is significantly upregulated in patients with non-small cell lung cancer. Asia Pac J Clin Oncol 2018, 14(5):e283-e288.
19. Ma C, Nie XG, Wang YL, Liu XH, Liang X, Zhou QL, Wu DP: CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma. Mol Med Rep 2019, 19(5):4205-4212.
20. Zhang H, Chen W, Fu X, Su X, Yang A: CBX3 promotes tumor proliferation by regulating G1/S phase via p21 downregulation and associates with poor prognosis in tongue squamous cell carcinoma. Gene 2018, 654:49-56.
21. Liu M, Huang F, Zhang D, Ju J, Wu XB, Wang Y, Wang Y, Wu Y, Nie M, Li Z et al: Heterochromatin protein HP1gamma promotes colorectal cancer progression and is regulated by miR-30a. Cancer Res 2015, 75(21):4593-4604.
22. Chen LY, Cheng CS, Qu C, Wang P, Chen H, Meng ZQ, Chen Z: CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer. Biochem Biophys Res Commun 2018, 500(3):691-697.
23. Zhang H, Fu X, Su X, Yang A: CBX3/HP1gamma is upregulated in tongue squamous cell carcinoma and is associated with an unfavorable prognosis. Exp Ther Med 2018, 15(5):4271-4276.
24. Zhong X, Kan A, Zhang W, Zhou J, Zhang H, Chen J, Tang S: CBX3/HP1gamma promotes tumor proliferation and predicts poor survival in hepatocellular carcinoma. Aging (Albany NY) 2019, 11(15):5483-5497.
25. Klungboonkrong V, Das D, McLennan G: Molecular Mechanisms and Targets of Therapy for Hepatocellular Carcinoma. J Vasc Interv Radiol 2017, 28(7):949-955.
26. Shen S, Dean DC, Yu Z, Duan Z: Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway. Hepatol Res 2019.
27. Chen LY, Cheng CS, Qu C, Wang P, Chen H, Meng ZQ, Chen Z: Overexpression of CBX3 in Pancreatic Adenocarcinoma Promotes Cell Cycle Transition-Associated Tumor Progression. Int J Mol Sci 2018, 19(6).
28. Rossi JJ: New hope for a microRNA therapy for liver cancer. Cell 2009, 137(6):990-992.
29. Ling H, Fabbri M, Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013, 12(11):847-865.
30. Chen JA, Yu Y, Xue C, Chen XL, Cui GY, Li J, Li KF, Ren ZG, Sun RR: Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis. Hepatobiliary Pancreat Dis Int 2019, 18(4):321-331.
31. Li P, Xiao Z, Luo J, Zhang Y, Lin L: MiR-139-5p, miR-940 and miR-193a-5p inhibit the growth of hepatocellular carcinoma by targeting SPOCK1. J Cell Mol Med 2019, 23(4):2475-2488.
32. Zan Y, Wang B, Liang L, Deng Y, Tian T, Dai Z, Dong L: MicroRNA-139 inhibits hepatocellular carcinoma cell growth through down-regulating karyopherin alpha 2. Journal of Experimental & Clinical Cancer Research 2019, 38(1).